

Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa

Yusuke Shimakawa, Maud Lemoine

► **To cite this version:**

Yusuke Shimakawa, Maud Lemoine. Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa. *The Lancet Gastroenterology and Hepatology*, Elsevier, 2017, 2 (6), pp.393. 10.1016/S2468-1253(17)30109-7 . pasteur-01740756

HAL Id: pasteur-01740756

<https://hal-pasteur.archives-ouvertes.fr/pasteur-01740756>

Submitted on 22 Mar 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Title

Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa

Authors

Yusuke Shimakawa, PhD,¹ Maud Lemoine, PhD²

Affiliations

¹ Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, 25-28 rue du Dr Roux, 75015, Paris, France

² Department of Surgery and Cancer, Liver Unit, Imperial College London, UK. Norfolk Place, London, W2 1NY, UK.

Corresponding Authors

Dr Yusuke Shimakawa

Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, 25-28 rue du Dr Roux, 75015, Paris, France

Email : yusuke.shimakawa@pasteur.fr

Phone : +33 (0)1 40 61 38 87

Fax : +33 (0)1 45 68 88 76

Keywords

Hepatitis B; hepatitis C; Africa; hepatocellular carcinoma; age; rate

Main Text

We read with interest the large-scale multicountry study by Ju Dong Yang and colleagues,¹ which described clinical characteristics of patients with hepatocellular carcinoma (HCC) in Africa. The investigators reported that the median age of HCC diagnosis was significantly lower in sub-Saharan Africa than in Egypt (46 vs 58 years, $p < 0.0001$) and that younger age at diagnosis in sub-Saharan Africa was also seen after stratification by the underlying cause: hepatitis B virus (HBV) or hepatitis C virus (HCV). They suggested that environmental or genetic factors might accelerate the onset of HCC in sub-Saharan Africa. Evidence from a systematic review of HCC case series has also shown younger ages at diagnosis of HBV-related HCC in sub-Saharan Africa than in Asia.²

Drawing such conclusions from case series is questionable, because the median age at HCC diagnosis can be strongly affected by the underlying population's age distribution. Indeed, the median age of the population in sub-Saharan Africa is lower than in Egypt (18 vs 25 years),³ reflecting the higher risks for competing causes of death in sub-Saharan Africa.

Age groups at high risk of HBV-related HCC can be best evaluated via age-specific incidence rates in a population-based cohort of chronic HBV carriers. However, to the best of our knowledge, only one such study has been done in sub-Saharan Africa;⁴ 405 people in The Gambia with chronic HBV infection (median age at baseline 10.8 years) were followed up for a median duration of 28 years, during which time six individuals developed HCC. All people who developed HCC were men, with a median age at diagnosis of 47.5 years (range: 38-67). The age-specific incidence in male chronic HBV carriers increased with age: incidences were 0.0, 304.2, 634.6, 563.3 and 1538.1 per 100,000 carrier-years for those 25-34, 35-44, 45-54, 55-64 and ≥ 65 years, respectively. These findings do not support the suggestion of earlier ages of diagnosis of HBV-related HCC in sub-Saharan Africa than elsewhere in the world.

Given the rarity of longitudinal cohorts of chronic HBV infection in Africa, the next most reliable way to evaluate this would be to compare the age-specific incidence rates of liver cancer in the general population between countries with similarly high HBV prevalence. We used cancer incidences estimated by the GLOBOCAN 2012 study (<http://globocan.iarc.fr/Default.aspx>) to look at male age-specific liver cancer incidence in The Gambian and China (figure). This figure also does not seem to support the notion of early age at HCC diagnosis in sub-Saharan Africa.

There is insufficient evidence to confirm the early onset of HBV-related HCC in sub-Saharan Africa. This issue underlines the importance of developing and maintaining population-based cancer registries in sub-Saharan Africa with well-defined catchment areas.⁵

Declaration of Interests

We declare that we have no conflict of interest.

References

- 1 Yang JD, Mohamed EA, Aziz AOA, *et al.* Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. *Lancet Gastroenterol Hepatol* 2017; **2**: 103–11.
- 2 de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. *Hepatology* 2015; **62**: 1190–200.

- 3 United Nations Population Division. World Population Prospects: The 2015 Revision. 2015. <https://esa.un.org/unpd/wpp/Download/Standard/Population/> (accessed March 21, 2017).
- 4 Shimakawa Y, Lemoine M, Njai HF, *et al.* Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. *Gut* 2016; **65**: 2007–16.
- 5 Shimakawa Y, Bah E, Wild CP, Hall AJ. Evaluation of data quality at the Gambia National Cancer Registry. *Int J Cancer* 2013; **132**: 658–65.

Figure: Age-specific incidence of liver cancer in men in The Gambia and China

